Symbion Biotech invests in biotech startup company  

Biotech company Evolva gets cash injection to support its drug discovery programme
Fledgling biotech company Evolva is to receive an up to DKK 13 million (USD 1.7 million) cash injection from the venture fund Symbion Capital. Evolva specialises in a technology that can discover, develop and manufacture small pharmaceutical molecules. The company's current pipeline products are targeted at the treatment of diseases such as cancer and diabetes. Besides Symbion capital, Prospero Biotech and Enggaard Folk & Fæ ApS are co-owners of the company. The news is reported in Jyllands-Posten today.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×